Skip to content
No results
Home
About
Executive Team
Board of Directors
Stategic Collaborations
Careers
Products
Zabadinostat (CXD101)
AT-101
PCV-001
Press Releases
Pipeline
Publications
Contact
Home
About
Executive Team
Board of Directors
Stategic Collaborations
Careers
Products
Zabadinostat (CXD101)
AT-101
PCV-001
Press Releases
Pipeline
Publications
Contact
Search
Menu
ESMO 2016 Poster 1
May 2, 2016
ESMO-2016-Poster-1
Share This Post
X
Facebook
LinkedIn
Messenger
WhatsApp
Posts navigation
← Celleron Therapeutics announces encouraging clinical results with its new cancer drug CXD101 in heavily pre-treated unresponsive cancer patients
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2) →
More Posts
IngenOx Therapeutics Receives New Patents for Compounds Inhibiting PRMT5
July 6, 2023
IngenOx Therapeutics Zabadinostat Approved by Hong Kong Drug Office to Start Liver Cancer Clinical Trial
April 24, 2023
IngenOx Therapeutics Drug Zabadinostat Enhances the Immune Response
March 7, 2023
